Evidence map›Paper›PMID 41764080›Full record

ReviewJournal of diabetes science and technology2026

Inpatient Use of Automated Insulin Delivery Systems.

Laya Chadalawada, Rohit Parab, Jenna M Feeley, Michael S Hughes, Francisco J Pasquel, Georgia M Davis

Abstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laya ChadalawadaDivision of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-0894-2356
Rohit ParabDivision of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-5362-6128
Jenna M FeeleyNutrition & Health Sciences Doctoral Program, Laney Graduate School, Emory University, Atlanta, GA, USA.
Michael S HughesDivision of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-3729-0350
Francisco J PasquelDivision of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-3845-6703
Georgia M DavisDivision of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-9671-0063

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378
6 · The paper itself

Abstract

introductionAutomated insulin delivery (AID) systems have improved outpatient glycemic control, reduced hypoglycemia, and enhanced quality of life for many people with diabetes. Interest is growing in translating these systems to inpatient care, where conventional insulin regimens are frequently associated with glycemic excursions and highly variable insulin requirements.

methodsWe conducted a narrative review of peer-reviewed studies evaluating inpatient use of AID systems, including both hospital-initiated AID and continuation of personal outpatient AID devices during hospitalization, across medical and surgical populations.

resultsAs outpatient adoption of AID systems increases, hospital clinicians are encountering patients using these technologies more frequently during admission. Available studies of both hospital-initiated AID and continued personal AID use during hospitalization suggest feasibility and safety, with improvements in time in range and no clear increase in hypoglycemia, although large-scale data remain limited. Broader implementation is constrained by important operational and regulatory barriers, including limited electronic health record integration, lack of device interoperability, regulatory clearance, and the absence of standardized institutional policies.

conclusionAs inpatient exposure to AID systems continues to expand, hospitals must develop infrastructure and operational policies to support safe use of personal devices and to evaluate hospital-initiated AID for patients with difficult-to-manage hyperglycemia. This review summarizes current evidence and highlights key challenges to integrating AID systems into routine inpatient diabetes care.

Indexed as

Diabetes MellitusHypoglycemic AgentsInsulinInsulin Infusion SystemsBlood GlucoseHumansInpatientsIntelligent SystemsBlood GlucoseHypoglycemic AgentsInsulinAID use in hospitalautomated insulin deliveryclosed-loop systems in hospitalinpatient AIDinpatient glycemic control

Identifiers

PMID41764080
PMCPMC12950530

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.